AlOtaibi SD, Elsisi HA, AlShammary MJ, et al. Evaluation of the psychiatric disorders among amphetamine addicts in rehabilitation centers: a cross-sectional analysis. J Toxicol. 2024;2024:1643693. EDN: KOFGID doi: 10.1155/2024/1643693.
DOI: 10.1155/2024/1643693

Alqarni H, Aldghim A, Alkahtani R, et al. Crystal methamphetamine and its effects on mental and oral health: a narrative review. Saudi Dent J. 2024;36(5):665–673. EDN: HRMVXA doi: 10.1016/j.sdentj.2024.02.011.
DOI: 10.1016/j.sdentj.2024.02.011

Nagy EK, Overby PF, Leyrer-Jackson JM, et al. Methamphetamine and the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) produce persistent effects on prefrontal and striatal microglial morphology and neuroimmune signaling following repeated binge-like intake in male and female rats. Brain Sci. 2024;14(5):435. EDN: IJAEQA doi: 10.3390/brainsci14050435.
DOI: 10.3390/brainsci14050435

Daiwile AP, Cadet JL. Modeling methamphetamine use disorder in mammals: sex differences in behavioral, biochemical, and transcriptional consequences. Adv Pharmacol. 2024;99:145–168. doi: 10.1016/bs.apha.2023.08.002.
DOI: 10.1016/bs.apha.2023.08.002

Elhadi K., Daiwile A.P., Cadet J.L. Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain. Neurosci Biobehav Rev. 2023;155:105440. EDN: YMEOBB doi: 10.1016/j.neubiorev.2023.105440.
DOI: 10.1016/j.neubiorev.2023.105440

Thurn D, Kuntsche E, Weber JA, et al. Development and validation of the amphetamine-type stimulants motive questionnaire in a clinical population. Front Psychiatry. 2017;8:183. doi: 10.3389/fpsyt.2017.00183.
DOI: 10.3389/fpsyt.2017.00183

Thurn D, Riedner A, Wolstein J. Use motives of patients with amphetamine-type stimulants use disorder and attention-deficit/hyperactivity disorder. Eur Addict Res. 2020;26(4–5):254–262. EDN: PCEACE doi: 10.1159/000508871.
DOI: 10.1159/000508871

Yates JR. Pharmacological treatments for methamphetamine use disorder: current status and future targets. Subst Abuse Rehabil. 2024;15:125–161. EDN: XJBGXU doi: 10.2147/SAR.S431273.
DOI: 10.2147/SAR.S431273

Poulton AS, Hibbert EJ, Champion BL, et al. Stimulants for the control of hedonic appetite. Front Pharmacol. 2016;7:105. doi: 10.3389/fphar.2016.00105.
DOI: 10.3389/fphar.2016.00105

Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754–763. doi: 10.4088/JCP.08m04902pur.
DOI: 10.4088/JCP.08m04902pur

Christensen L, Sasané R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010;26(4):977–989. doi: 10.1185/03007991003673617.
DOI: 10.1185/03007991003673617

Schein J, Cloutier M, Gauthier-Loiselle M, et al. Treatment preferences of adult patients with attention-deficit/hyperactivity disorder – a discrete choice experiment. Patient Prefer Adherence. 2024;18:1651–1664. EDN: OXKXTG doi: 10.2147/PPA.S467724.
DOI: 10.2147/PPA.S467724

Ferrin M, Häge A, Swanson J, et al. Medication adherence and persistence in children and adolescents with attention deficit hyperactivity disorder (ADHD): a systematic review and qualitative update. Eur Child Adolesc Psychiatry. EDN: SVIHMG doi: 10.1007/s00787-024-02538-z.
DOI: 10.1007/s00787-024-02538-z

Urakov AL. Amphetamines: quality, methods of preparation, composition, pharmacological effects. Medical examination problems. 2014;14(1):50–52. (In Russ.) EDN: SCOSKR

Shabanov PD, Lebedev AA, Yakushina ND, et al. Effect of amphetamine on behavioral patterns of obsessive-compulsive and addictive gambling in a rat marble test. Reviews on Clinical Pharmacology and Drug Therapy. 2016;14(3):46–52. EDN: WWUKGT doi: 10.17816/RCF14346-52.
DOI: 10.17816/RCF14346-52

Urakov AL, Shabanov PD. Opioid, cannabinoid, cocaine, and methamphetamine epidemics: history, risk factors associated with them, and characteristics of drug action. Psychopharmacology and Biological Narcology. 2023;14(4):251–262. EDN: RSBFCF doi: 10.17816/phbn568586.
DOI: 10.17816/phbn568586

Methamphetamine. In: PubChem [Internet]. [cited 2025 Feb 25]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Methamphetaminehttps://pubchem.ncbi.nlm.nih.gov/compound/Methamphetamine

Urakov AL, Shabanov PD. Idealization in pharmacology and pharmacy: symbol of the chemical formula of one molecule of a substance and a real pharmaceutical product. Reviews on Clinical Pharmacology and Drug Therapy. 2023;21(4):319–327. doi: 10.17816/RCF593274.
DOI: 10.17816/RCF593274

Ling LJ, Clark RF, Erickson TB, et al. Secrets of toxicology. Saint Petersburg: BINOM, Dialect; 2006. 376 p. EDN: QLLMBN (In Russ.)

Urakov AL. Drugs-amphetamines (ephedrine, methamphetamine, pervitin, ice, crystal, screw): mechanism of action. Advances in current natural sciences. 2014;5(1):43–48. EDN: SBDKGV

Methamphetamine: everything you need to know. In: Stonegate center [Internet] [cited 2025 Feb 25]. Available from: https://stonegatecenter.com/blog/2019/06/10/methamphetamine-everything-you-need-to-know/https://stonegatecenter.com/blog/2019/06/10/methamphetamine-everything-you-need-to-know/

Kinner SA, Degenhardt L. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm. Drug Alcohol Rev. 2008;27(3):292–300. doi: 10.1080/09595230801919452.
DOI: 10.1080/09595230801919452

Spivak B, Shepherd S, Borschmann R, et al. Crystalline methamphetamine (ice) use prior to youth detention: A forensic concern or a public health issue? PLoS One. 2020;15(5):e0229389. EDN: DXIIJF doi: 10.1371/journal.pone.0229389.
DOI: 10.1371/journal.pone.0229389

Deen H, Kershaw S, Newton N, et al. Stigma, discrimination and crystal methamphetamine (‘ice’): current attitudes in Australia. Int J Drug Policy. 2021;87:102982. EDN: VPJMPQ doi: 10.1016/j.drugpo.2020.102982.
DOI: 10.1016/j.drugpo.2020.102982

Scott R. Methamphetamine dependence in Australia-why is “ice” (crystal meth) so addictive?. Psychiatr Psychol Law. 2023;31(4):671–704. doi: 10.1080/13218719.2023.2206870.
DOI: 10.1080/13218719.2023.2206870

Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085–1099. doi: 10.1111/j.1360-0443.2009.02564.x.
DOI: 10.1111/j.1360-0443.2009.02564.x

Douglass CH, Early EC, Wright CJC, et al. “Just not all ice users do that”: investigating perceptions and potential harms of Australia’s ice destroys lives campaign in two studies. Harm Reduct J. 2017;14(1):45. doi: 10.1186/s12954-017-0175-9.
DOI: 10.1186/s12954-017-0175-9

Cartwright K, Tait RJ. Service providers’ experience of methamphetamine and the portrayal of the ‘ice epidemic’ in remote Australia. Aust J Rural Health. 2019;27(1):83–87. doi: 10.1111/ajr.12483.
DOI: 10.1111/ajr.12483

Gendera S, Treloar C, Reilly R, et al. “Even though you hate everything that’s going on, you know they are safer at home”: the role of Aboriginal and Torres Strait Islander families in methamphetamine use harm reduction and their own support needs. Drug Alcohol Rev. 2022;41(6):1428–1439. EDN: BLYJNI doi: 10.1111/dar.13481.
DOI: 10.1111/dar.13481

Mu LL, Wang Y, Wang LJ, et al. Associations of executive function and age of first use of methamphetamine with methamphetamine relapse. Front Psychiatry. 2022;13:971825. EDN: AYHZAJ doi: 10.3389/fpsyt.2022.971825.
DOI: 10.3389/fpsyt.2022.971825

Urakov AL. How drugs work inside us: a self-help guide to pharmacology. Izhevsk: Udmurtia; 1993. 429 p. (In Russ.)

Altshuler RD, Lin H, Li X. Neural mechanisms underlying incubation of methamphetamine craving: a mini-review. Pharmacol Biochem Behav. 2020;199:173058. EDN: GSQJOF doi: 10.1016/j.pbb.2020.173058.
DOI: 10.1016/j.pbb.2020.173058

Daiwile AP, Jayanthi S, Cadet JL. Sex differences in methamphetamine use disorder perused from pre-clinical and clinical studies: potential therapeutic impacts. Neurosci Biobehav Rev. 2022;137:104674. EDN: MDXXYI doi: 10.1016/j.neubiorev.2022.104674.
DOI: 10.1016/j.neubiorev.2022.104674

Fort TD, Azuma MC, Laux DA, et al. Environmental enrichment and sex, but not n-acetylcysteine, alter extended-access amphetamine self-administration and cue-seeking. Behav Brain Res. 2025;476:115261. doi: 10.1016/j.bbr.2024.115261.
DOI: 10.1016/j.bbr.2024.115261

Daiwile AP, Jayanthi S, Ladenheim B, et al. Sex differences in escalated methamphetamine self-administration and altered gene expression associated with incubation of methamphetamine seeking. Int J Neuropsychopharmacol. 2019;22(11):710–723. doi: 10.1093/ijnp/pyz050.
DOI: 10.1093/ijnp/pyz050

Daiwile AP, Jayanthi S, Cadet JL. Sex- and brain region-specific changes in gene expression in male and female rats as consequences of methamphetamine self-administration and abstinence. Neuroscience. 2021;452:265–279. EDN: BULWDV doi: 10.1016/j.neuroscience.2020.11.025.
DOI: 10.1016/j.neuroscience.2020.11.025

Miller AE, Daiwile AP, Cadet JL. Sex-dependent alterations in the mrna expression of enzymes involved in dopamine synthesis and breakdown after methamphetamine self-administration. Neurotox Res. 2022;40(5):1464–1478. EDN: TUOIZM doi: 10.1007/s12640-022-00545-z.
DOI: 10.1007/s12640-022-00545-z

Daiwile AP, Sullivan P, Jayanthi S, et al. Sex-specific alterations in dopamine metabolism in the brain after methamphetamine self-administration. Int J Mol Sci. 2022;23(8):4353. EDN: EVXAGF doi: 10.3390/ijms23084353.
DOI: 10.3390/ijms23084353

Scheibein F, Wells J, Henriques S, et al. “Slam sex” – sexualized injecting drug use (“SIDU”) amongst men who have sex with men (MSM) – a scoping review. J Homosex. 2021;68(14):2344–2358. doi: 10.1080/00918369.2020.1804258.
DOI: 10.1080/00918369.2020.1804258

Íncera-Fernández D, Gámez-Guadix M, Moreno-Guillén S. Mental health symptoms associated with sexualized drug use (chemsex) among men who have sex with men: a systematic review. Int J Environ Res Public Health. 2021;18(24):13299. EDN: MRNMYG doi: 10.3390/ijerph182413299.
DOI: 10.3390/ijerph182413299

Hsu JH, Huang P, Li CW, et al. Experiences of harm and mental ill-health among gay, bisexual and other men-who-have-sex-with-men who use methamphetamine or GHB/GBL in different combinations: findings from the COMeT study in Taiwan. Harm Reduct J. 2024;21(1):181. EDN: YVSMVG doi: 10.1186/s12954-024-01094-8.
DOI: 10.1186/s12954-024-01094-8

Wang H, Jonas KJ, Guadamuz TE. Chemsex and chemsex associated substance use among men who have sex with men in Asia: a systematic review and meta-analysis. Drug Alcohol Depend. 2023;243:109741. EDN: UOTRCN doi: 10.1016/j.drugalcdep.2022.109741.
DOI: 10.1016/j.drugalcdep.2022.109741

Basova LV, Riley T, Franklin D, et al. Identifying methamphetamine use predictors in HIV infection: Immune-dopaminergic signatures in peripheral leukocytes and the role of COMT genotype. Brain Behav Immun Health. 2024;42:100873. EDN: DADSJX doi: 10.1016/j.bbih.2024.100873.
DOI: 10.1016/j.bbih.2024.100873

Basova LV, Lindsey A, McGovern A, et al. MRP8/14 Is a molecular signature triggered by dopamine in hiv latent myeloid targets that increases hiv transcription and distinguishes hiv+ methamphetamine users with detectable csf viral load and brain pathology. Viruses. 2023;15(6):1363. EDN: HOFCKQ doi: 10.3390/v15061363.
DOI: 10.3390/v15061363

Fattakhov N, Torices S, Stangis M, et al. Synergistic impairment of the neurovascular unit by hiv-1 infection and methamphetamine use: implications for hiv-1-associated neurocognitive disorders. Viruses. 2021;13(9):1883. EDN: QWSIGA doi: 10.3390/v13091883.
DOI: 10.3390/v13091883

Miao L, Wang H, Li Y, et al. Mechanisms and treatments of methamphetamine and HIV-1 co-induced neurotoxicity: a systematic review. Front Immunol. 2024;15:1423263. EDN: QRXDPE doi: 10.3389/fimmu.2024.1423263.
DOI: 10.3389/fimmu.2024.1423263

Urakov AL, Urakova NA, Shubina ZV, et al. Hypertonic activity of injection solutions can cause post-injection complications (review). Drug development & registration. 2023;12(2):164–173. EDN: GDSJTI doi: 10.33380/2305-2066-2023-12-2-164-173..
DOI: 10.33380/2305-2066-2023-12-2-164-173

Urakov A, Urakova N. Osmotic activity of drugs is an important factor of their local action at their Injection site: what we don’t use to prevent post-injection abscesses. Journal of Pharmaceutical Research International. 2021;33(59B):647–650. EDN: QSLGXF doi: 10.9734/jpri/2021/v33i59B34428..
DOI: 10.9734/jpri/2021/v33i59B34428

Urakov A, Urakova N, Samorodov A, et al. Thermal imaging of local skin temperature as part of quality and safety assessment of injectable drugs. Heliyon. 2023;10(1):e23417. EDN: DZQJJW doi: 10.1016/j.heliyon.2023.e23417.
DOI: 10.1016/j.heliyon.2023.e23417

Urakov AL. Nikolau syndrome: necrotic activity of drugs and ways to prevent post-injection abscesses (in memory of professor László A Gömze). Creative surgery and oncology. 2021;12(2):159–163. doi: 10.24060/2076-3093-2022-12-2-.
DOI: 10.24060/2076-3093-2022-12-2-

Vilca SJ, Margetts AV, Höglund L, et al. Microglia contribute to methamphetamine reinforcement and reflect persistent transcriptional and morphological adaptations to the drug. Brain Behav Immun. 2024;120:339–351. EDN: RAYXAE doi: 10.1016/j.bbi.2024.05.038.
DOI: 10.1016/j.bbi.2024.05.038

Davis IR, Coldren SA, Li X. Methamphetamine seeking after prolonged abstinence is associated with activated projections from anterior intralaminar nucleus of thalamus to dorsolateral striatum in female rats. Pharmacol Biochem Behav. 2021;200:173087. EDN: ETUCDZ doi: 10.1016/j.pbb.2020.173087.
DOI: 10.1016/j.pbb.2020.173087

Vilca SJ, Margetts AV, Fleites I, et al. Microglia contribute to methamphetamine reinforcement and reflect persistent transcriptional and morphological adaptations to the drug. Preprint. bioRxiv. 2024;2023.10.19.563168. EDN: RAYXAE doi: 10.1101/2023.10.19.563168.
DOI: 10.1101/2023.10.19.563168

Elhadi K, Daiwile AP, Cadet JL. Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain. Neurosci Biobehav Rev. 2023. EDN: YMEOBB doi: 10.1016/j.neubiorev.2023.105440.
DOI: 10.1016/j.neubiorev.2023.105440

Daiwile AP, McCoy MT, Ladenheim B, et al. Incubation of methamphetamine craving in punishment-resistant individuals is associated with activation of specific gene networks in the rat dorsal striatum. Mol Psychiatry. 2024;29(7):1990–2000. EDN: VGCCQI doi: 10.1038/s41380-024-02455-2.
DOI: 10.1038/s41380-024-02455-2

Hámor PU, Knackstedt LA, Schwendt M. The role of metabotropic glutamate receptors in neurobehavioral effects associated with methamphetamine use. Int Rev Neurobiol. 2023;168:177–219. doi: 10.1016/bs.irn.2022.10.005.
DOI: 10.1016/bs.irn.2022.10.005

Kershaw S, Sunderland M, Grager A, et al. Perceived barriers to help-seeking for people who use crystal methamphetamine: perspectives of people with lived experience, family members and health workers. Drug Alcohol Rev. 2024;43(7):1929–1939. EDN: OEVMKP doi: 10.1111/dar.13897.
DOI: 10.1111/dar.13897

Chalmers J., Lancaster K., Hughes C. The stigmatisation of ‘ice’ and under-reporting of meth/amphetamine use in general population surveys: A case study from Australia. Int J Drug Policy. 2016;36:15–24. doi: 10.1016/j.drugpo.2016.06.001.
DOI: 10.1016/j.drugpo.2016.06.001

Chan GCK, Sun T, Lim C, et al. Did the under-reporting of meth/amphetamine use increase in a general population survey in Australia as negative media coverage increased? Addiction. 2022;117(6):1787–1793. EDN: TBFTCY doi: 10.1111/add.15783.
DOI: 10.1111/add.15783

Whitely M, Allsop S. Look west for Australian evidence of the relationship between amphetamine-type stimulant prescribing and meth/amphetamine use. Drug Alcohol Rev. 2020;39(5):519–524. EDN: PHCJTT doi: 10.1111/dar.13067.
DOI: 10.1111/dar.13067

Goodchild JH, Donaldson M, Mangini DJ. Methamphetamine abuse and the impact on dental health. Dent Today. 2007;26(5):124–131.

Kaye S, McKetin R, Duflou J, et al. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102(8):1204–1211. doi: 10.1111/j.1360-0443.2007.01874.x.
DOI: 10.1111/j.1360-0443.2007.01874.x

Courtney KE, Ray LA. Clinical neuroscience of amphetamine-type stimulants: from basic science to treatment development. Prog Brain Res. 2016;223:295–310. doi: 10.1016/bs.pbr.2015.07.010.
DOI: 10.1016/bs.pbr.2015.07.010

Shen W, Li L, Liu Y, et al. The motivation against change in male methamphetamine users in the compulsory detoxification setting. Front Psychiatry. 2023;14:1022926. EDN: MZOWTV doi: 10.3389/fpsyt.2023.1022926.
DOI: 10.3389/fpsyt.2023.1022926

Fort TD, Cain ME. Inefficacy of N-acetylcysteine in mitigating cue-induced amphetamine-seeking. Addict Neurosci. 2023;8:100119. doi: 10.1016/j.addicn.2023.100119.
DOI: 10.1016/j.addicn.2023.100119

Garcia EJ, Cain ME. Isolation housing elevates amphetamine seeking independent of nucleus accumbens glutamate receptor adaptations. Eur J Neurosci. 2021;54(7):6382–6396. EDN: HWHQLH doi: 10.1111/ejn.15441.
DOI: 10.1111/ejn.15441

Garcia EJ, Arndt DL, Cain ME. Dynamic interactions of ceftriaxone and environmental variables suppress amphetamine seeking. Brain Res. 2019;1712:63–72. doi: 10.1016/j.brainres.2019.01.044.
DOI: 10.1016/j.brainres.2019.01.044

Gupta M, Gupta N, Esang M, et al. Refractory methamphetamine-induced psychosis: an emerging crisis in rural america and the role of amantadine in therapeutics. Cureus. 2022;14(3):e22871. EDN: EKQNHG doi: 10.7759/cureus.22871.
DOI: 10.7759/cureus.22871

Wearne TA, Cornish JL. A comparison of methamphetamine-induced psychosis and schizophrenia: a review of positive, negative, and cognitive symptomatology. Front Psychiatry. 2018;9:491. doi: 10.3389/fpsyt.2018.00491.
DOI: 10.3389/fpsyt.2018.00491

Ahmadkhaniha H, Ayazi N, Alavi K, et al. The comparison between positive and negative symptoms severity in prolonged methamphetamine-induced psychotic disorder and schizophrenia. Basic Clin Neurosci. 2022;13(3):325–333. EDN: HNLKNR doi: 10.32598/bcn.2021.2837.1.
DOI: 10.32598/bcn.2021.2837.1

McKetin R, Baker AL, Dawe S, et al. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders. Psychiatry Res. 2017;251:349–354. doi: 10.1016/j.psychres.2017.02.028.
DOI: 10.1016/j.psychres.2017.02.028

McKetin R, Gardner J, Baker AL, et al. Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users. Psychiatry Res. 2016;238:166–171. doi: 10.1016/j.psychres.2016.02.038.
DOI: 10.1016/j.psychres.2016.02.038

McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013;70(3):319–324. doi: 10.1001/jamapsychiatry.2013.283.
DOI: 10.1001/jamapsychiatry.2013.283

Eslami-Shahrbabaki M, Fekrat A, Mazhari S. A study of the prevalence of psychiatric disorders in patients with methamphetamine-induced psychosis. Addict Health. 2015;7(1–2):37–46.

Nohesara S, Mostafavi Abdolmaleky H, Thiagalingam S. Substance-induced psychiatric disorders, epigenetic and microbiome alterations, and potential for therapeutic interventions. Brain Sci. 2024;14(8):769. EDN: ERSRXW doi: 10.3390/brainsci14080769.
DOI: 10.3390/brainsci14080769

Johnson K, Pinchuk I, Melgar MIE, et al. The global movement towards a public health approach to substance use disorders. Ann Med. 2022;54(1):1797–1808. EDN: CJFBXO doi: 10.1080/07853890.2022.2079150.
DOI: 10.1080/07853890.2022.2079150

Souilm N. Equine-assisted therapy effectiveness in improving emotion regulation, self-efficacy, and perceived self-esteem of patients suffering from substance use disorders. BMC Complement Med Ther. 2023;23(1):363. EDN: LLYSIM doi: 10.1186/s12906-023-04191-6.
DOI: 10.1186/s12906-023-04191-6

Marshall B.D., Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010;105(6):991–1002. doi: 10.1111/j.1360-0443.2010.02932.x.
DOI: 10.1111/j.1360-0443.2010.02932.x

Darke S, Kaye S, McKetin R, et al. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27(3):253–262. doi: 10.1080/09595230801923702.
DOI: 10.1080/09595230801923702

Lamyai W, Pono K, Indrakamhaeng D, et al. Risks of psychosis in methamphetamine users: cross-sectional study in Thailand. BMJ Open. 2019;9(10):e032711. doi: 10.1136/bmjopen-2019-032711.
DOI: 10.1136/bmjopen-2019-032711

Turan Ç, Budak E, Şenormancı G, et al. Risk of relapse assessment scale for metamphetamine abusers: reliability and validity study of the turkish version. Psychiatry Clin Psychopharmacol. 2023;33(3):156–162. EDN: QMPZCV doi: 10.5152/pcp.2023.23671.
DOI: 10.5152/pcp.2023.23671

Temmingh HS, van den Brink W, Howells F, et al. Methamphetamine use and antipsychotic-related extrapyramidal side-effects in patients with psychotic disorders. J Dual Diagn. 2020;16(2):208–217. EDN: HZSCYQ doi: 10.1080/15504263.2020.1714099.
DOI: 10.1080/15504263.2020.1714099

Espiridion ED, Charron L. Methamphetamine use and suicide: a case report and brief review of literature. Cureus. 2024;16(7):e64835. EDN: EYUZVO doi: 10.7759/cureus.64835.
DOI: 10.7759/cureus.64835

Calcaterra SL, Yamkovoy K, Swathi PA, et al. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015–2019. Drug Alcohol Depend. 2024;262:111409. EDN: SYCDFX doi: 10.1016/j.drugalcdep.2024.111409.
DOI: 10.1016/j.drugalcdep.2024.111409

Han B, Compton WM, Jones CM, et al. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry. 2021;78(12):1329–1342. EDN: SHWBJD doi: 10.1001/jamapsychiatry.2021.2588.
DOI: 10.1001/jamapsychiatry.2021.2588

Carrico AW, Ryan DT, Berona J, et al. HIV, inflammation, and initiation of methamphetamine use in sexual and gender minorities assigned male at birth. Proc Natl Acad Sci USA. 2024;121(41):e2407046121. EDN: BOLKDS doi: 10.1073/pnas.2407046121.
DOI: 10.1073/pnas.2407046121

Han B, Cotto J, Etz K, et al. Methamphetamine overdose deaths in the US by sex and race and ethnicity. JAMA Psychiatry. 2021;78(5):564–567. EDN: DEUWWE doi: 10.1001/jamapsychiatry.2020.4321.
DOI: 10.1001/jamapsychiatry.2020.4321

Walker SL, Mehtani NJ, Parikh NI. Facing a tsunami: methamphetamine heart failure demands novel approaches. JACC Adv. 2024;3(7):100838. doi: 10.1016/j.jacadv.2024.100838.
DOI: 10.1016/j.jacadv.2024.100838

Roy RJ, Parvaz MA, Wakabayashi KT, et al. Methamphetamine-related working memory difficulties underpinned by reduced frontoparietal responses. Addict Biol. 2024;29(10):e13444. EDN: HPLHJB doi: 10.1111/adb.13444.
DOI: 10.1111/adb.13444

Vincent B, Shukla M. The common denominators of parkinson’s disease pathogenesis and methamphetamine abuse. Curr Neuropharmacol. 2024;22(13):2113–2156. EDN: CZKEKY doi: 10.2174/1570159X21666230907151226.
DOI: 10.2174/1570159X21666230907151226